15 December 2025, Geneva, Switzerland - The United Nations Institute for Training and Research (UNITAR) is pleased to share the inclusion of its public-private Plasma4Life initiative in Takeda’s new report, Access to Medicine 2025, which highlights ongoing efforts to strengthen patient access to essential treatments in emerging markets. The report includes a dedicated section on Plasma4Life entitled, “Planning for patient access through sustainable supply of plasma and plasma-derived therapies.”
Through this collaboration, UNITAR and its partners, including Takeda are working to strengthen the resilience of healthcare systems and support more sustainable access to plasma and plasma-derived therapies. Recognising the complexity of global plasma supply chains and the need for locally tailored, context-specific solutions, Takeda joined the UN-led Plasma4Life initiative in 2022 as a founding and funding knowledge partner.
Plasma4Life brings together policymakers, experts, patient groups, and industry stakeholders to share expertise and co-develop practical, evidence-based solutions aimed at improving national plasma ecosystems. Since its launch in April 2023, the initiative has been supported by additional knowledge partners from international patient organizations and industry associations.
A central component of the initiative is the online knowledge hub, Plasma4. Life, which offers open-access resources including scientific evidence, international references, national regulatory frameworks, and educational webinars. By making these materials freely available, Plasma4Life supports policymakers, healthcare professionals, patient groups, and experts in staying informed, learning from global experiences, and applying proven approaches to their own national contexts.
In parallel, country-level multistakeholder working groups, including those established in Argentina and Malaysia, are undertaking mapping of national plasma systems, identifying key gaps, and co-creating locally relevant and actionable solutions to strengthen healthcare resilience and improve patient access.
The inclusion of this collaboration in Access to Medicine 2025 reflects the importance of cross-sector cooperation, knowledge sharing, and capacity development in advancing equitable access to life-saving plasma and plasma-derived therapies.